PSI Sci
New here? Follow the money and the votes · Not sure of your district? Find your U.S. House member · Find your state legislators

H.R. 5030: DIVERSE Trials Act

Before you vote › Federal bills

H.R. 5030: DIVERSE Trials Act

117th Congress · introduced 2021-08-13 · Health · Latest: Referred to the Subcommittee on Health.

federal

Follow this bill, step by step

  1. Where it came from: introduced 2021-08-13 · official record
  2. Who proposed it: Rep. Ruiz, Raul [D-CA-36] · what a sponsor is
  3. What happened next: no floor votes in our records yet. Why?
  4. Where it stands now: Referred to the Subcommittee on Health. Not final yet: this can still change. We check for updates every day.
  5. If it becomes law and spends money: follow the money to money laws, then agencies and contracts and grants.

What does this mean?

Official title

DIVERSE Trials Act

Plain summary

Diversifying Investigations Via Equitable Research Studies for Everyone Trials Act or the DIVERSE Trials Act This bill requires activities to increase diversity in clinical trials. It also expands reporting by laboratories that test for and diagnose COVID-19 and requires a study on data collection and data sharing during public health emergencies. Specifically, the Food and Drug Administration (FDA) must issue guidance on decentralized clinical trials to promote meaningful demographic and geographic diversity in patient engagement, enrollment, and participation. Decentralized clinical trials include those executed through telemedicine or other digital technologies to allow for the remote collection and assessment of clinical trial data. The FDA may also work with foreign regulators to harmonize international regulations governing decentralized clinical trials and the use of digital health technology. In addition, the Department of Health and Human Services (HHS) may support community education, outreach, and recruitment activities for clinical trials of treatments for conditions that disproportionately impact populations underrepresented in clinical trials. The bill also specifies that drug or device manufacturers may provide, subject to some limits, free digital health technologies and other remuneration to patients in approved clinical trials without violating laws that address fraud and abuse in federal programs. Furthermore, laboratories that test for and diagnose COVID-19 must report additional demographic data, including information about social determinants of health. HHS must also contract with the National Academy of Medicine to study and propose a design for an interoperable platform to facilitate data sharing during public health emergencies.

Congressional Research Service summary (Introduced in House), quoted unchanged (nonpartisan). Read the source.

What a vote does

A “Yea” vote

If it passes both chambers and is signed, it becomes law.

A “Nay” vote

If it is not passed, current law stays as it is.

PSI Sci description of the legislative step (not an opinion).

What does this mean? (plain words)

Official text

DIVERSE Trials Act

Source: Congressional Research Service summary (Introduced in House)

AI explanation – may be wrong, check the official text

No AI explanation yet. It takes up to a minute to write and is then saved for everyone.

Limited to a few requests an hour per person.

The strongest published arguments

Arguments for (supporters)

Needs sources: no published arguments on this side yet. We only show items backed by a published source. Suggest one.

Arguments against (opponents)

Needs sources: no published arguments on this side yet. We only show items backed by a published source. Suggest one.

Alternatives

Needs sources: no published alternatives yet (for example a different bill, a law instead of an amendment, or keeping current law). We only show items backed by a published source. Suggest one.

How did my representative vote? · This bill's floor votes

Officials and money

Sponsor: Rep. Ruiz, Raul [D-CA-36] · 54 cosponsors

Cost estimate: No cost estimate published yet.

Cosponsors on this site

Maria Elvira Salazar (R-FL), Deborah K. Ross (D-NC), Darren Soto (D-FL), Suzanne Bonamici (D-OR), Kweisi Mfume (D-MD), John B. Larson (D-CT), Julia Brownley (D-CA), Salud O. Carbajal (D-CA), Dwight Evans (D-PA), Joyce Beatty (D-OH), Lisa Blunt Rochester (D-DE), John H. Rutherford (R-FL), Pramila Jayapal (D-WA), Emanuel Cleaver (D-MO), Sara Jacobs (D-CA), Josh Harder (D-CA), Sharice Davids (D-KS), Stephen F. Lynch (D-MA), Peter Welch (D-VT), Mike Quigley (D-IL), Ro Khanna (D-CA), Doris O. Matsui (D-CA), James P. McGovern (D-MA), Ilhan Omar (D-MN), Lauren Underwood (D-IL), Mike Levin (D-CA), Chris Pappas (D-NH), Steve Cohen (D-TN), Maxine Waters (D-CA), Jason Crow (D-CO), Mark Pocan (D-WI), Mark DeSaulnier (D-CA)

Sponsor's campaign money: Rep. Ruiz, Raul [D-CA-36] reported raising $2.5 million (2025–2026). Details. Shown for context only; it does not mean any donor supported this bill.

No linked floor roll calls in our collected records yet. This does not mean the bill has never had a vote. Check the official bill history.

Words on this page, explained (2)
Bill
A proposed law. It becomes law only if it passes the legislature and is signed by the president or governor (or a veto is overridden).
Rulemaking
The process agencies use to write regulations that carry out laws passed by Congress or a legislature. Usually an agency publishes a proposed rule, takes public comments, then publishes a final rule.

Plain meanings written from linked sources. All words.

Sources

Record fed-us-cong117-hr5030 · catalog fed-us-congress-bills-cong117 · updated 2026-11-15 by psicol fed-bills-cong117